tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2023 Jan 27;10(2)
fad043.
doi: 10.1093/ofid/ofad043. eCollection 2023 Feb.
Pneumocystis jirovecii Infections Among COVID-19 Patients: A Case Series and Literature Review
Paul Amstutz[SUP] 1 [/SUP], Nathan C Bahr[SUP] 2 [/SUP], Karen Snyder[SUP] 2 [/SUP], D Matthew Shoemaker[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Pneumocystis jirovecii pneumonia (PCP) is a serious, emerging complication of coronavirus disease 2019 (COVID-19).
Methods: We performed a systematic review of published cases. We describe 6 new cases of PCP/COVID-19 coinfection. Among our cases (n = 6) and those in the literature (n = 69) with available data, the median age (interquartile range [IQR]) was 59 (44-77) years (n = 38), 72% (47/65) were male, and the mortality rate was 30.9% (21/68).
Results: Long-term corticosteroid use was noted in 45.1% (23/51), advanced HIV infection (defined as a CD4 count <200 cells/μL) in 17.6% (9/51), and antineoplastic chemotherapy in 13.7% (7/51), consistent with known PCP risk factors. Notably, 56.7% (38/47) had verifiable risk factors for PCP (high-dose corticosteroids, immunosuppressive therapy, and HIV infection) before COVID-19 infection. A median absolute lymphocyte count (IQR) of 0.61 (0.28-0.92) ×10[SUP]3[/SUP] cells/mm[SUP]3[/SUP] (n = 23) and CD4 count (IQR) of 66 (33-291.5) cells/mm[SUP]3[/SUP] (n = 20) were also discovered among the study population.
Conclusions: These findings suggest a need for greater attention to PCP risk factors among COVID-19 patients and consideration of PCP prophylaxis in these high-risk populations.
Keywords: COVID-19; PCP; Pneumocystis jirovecii; coinfection; immunocompromised; invasive fungal infections; pneumocystis.
. 2023 Jan 27;10(2)
fad043.doi: 10.1093/ofid/ofad043. eCollection 2023 Feb.
Pneumocystis jirovecii Infections Among COVID-19 Patients: A Case Series and Literature Review
Paul Amstutz[SUP] 1 [/SUP], Nathan C Bahr[SUP] 2 [/SUP], Karen Snyder[SUP] 2 [/SUP], D Matthew Shoemaker[SUP] 2 [/SUP]
Affiliations
- PMID: 36817747
- PMCID: PMC9933943
- DOI: 10.1093/ofid/ofad043
Abstract
Background: Pneumocystis jirovecii pneumonia (PCP) is a serious, emerging complication of coronavirus disease 2019 (COVID-19).
Methods: We performed a systematic review of published cases. We describe 6 new cases of PCP/COVID-19 coinfection. Among our cases (n = 6) and those in the literature (n = 69) with available data, the median age (interquartile range [IQR]) was 59 (44-77) years (n = 38), 72% (47/65) were male, and the mortality rate was 30.9% (21/68).
Results: Long-term corticosteroid use was noted in 45.1% (23/51), advanced HIV infection (defined as a CD4 count <200 cells/μL) in 17.6% (9/51), and antineoplastic chemotherapy in 13.7% (7/51), consistent with known PCP risk factors. Notably, 56.7% (38/47) had verifiable risk factors for PCP (high-dose corticosteroids, immunosuppressive therapy, and HIV infection) before COVID-19 infection. A median absolute lymphocyte count (IQR) of 0.61 (0.28-0.92) ×10[SUP]3[/SUP] cells/mm[SUP]3[/SUP] (n = 23) and CD4 count (IQR) of 66 (33-291.5) cells/mm[SUP]3[/SUP] (n = 20) were also discovered among the study population.
Conclusions: These findings suggest a need for greater attention to PCP risk factors among COVID-19 patients and consideration of PCP prophylaxis in these high-risk populations.
Keywords: COVID-19; PCP; Pneumocystis jirovecii; coinfection; immunocompromised; invasive fungal infections; pneumocystis.